(NASDAQ: BFRI) Biofrontera's forecast annual revenue growth rate of 14.29% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Biofrontera's revenue in 2026 is $43,202,000.On average, 4 Wall Street analysts forecast BFRI's revenue for 2026 to be $610,629,885, with the lowest BFRI revenue forecast at $580,938,931, and the highest BFRI revenue forecast at $634,738,582. On average, 3 Wall Street analysts forecast BFRI's revenue for 2027 to be $714,311,365, with the lowest BFRI revenue forecast at $686,297,648, and the highest BFRI revenue forecast at $735,321,653.
In 2028, BFRI is forecast to generate $827,492,926 in revenue, with the lowest revenue forecast at $795,049,252 and the highest revenue forecast at $851,832,083.